Epstein-Barr virus encephalitis in solid organ transplantation

Jillian S.Y. Lau, Zhi Mei Low, Iain Abbott, Lani Shochet, John Kanellis, A. Richard Kitching, Tony M. Korman

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes.

Original languageEnglish
Pages (from-to)212-217
Number of pages6
JournalNew Microbiologica
Volume40
Issue number3
Publication statusPublished - 1 Jul 2017

Keywords

  • Encephalitis
  • Epstein-Barr virus
  • Immunosuppression
  • Transplant

Cite this

@article{bfa0655a51ce48fda5732b8364a4468e,
title = "Epstein-Barr virus encephalitis in solid organ transplantation",
abstract = "Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes.",
keywords = "Encephalitis, Epstein-Barr virus, Immunosuppression, Transplant",
author = "Lau, {Jillian S.Y.} and Low, {Zhi Mei} and Iain Abbott and Lani Shochet and John Kanellis and Kitching, {A. Richard} and Korman, {Tony M.}",
year = "2017",
month = "7",
day = "1",
language = "English",
volume = "40",
pages = "212--217",
journal = "New Microbiologica",
issn = "1121-7138",
number = "3",

}

Epstein-Barr virus encephalitis in solid organ transplantation. / Lau, Jillian S.Y.; Low, Zhi Mei; Abbott, Iain; Shochet, Lani; Kanellis, John; Kitching, A. Richard; Korman, Tony M.

In: New Microbiologica, Vol. 40, No. 3, 01.07.2017, p. 212-217.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Epstein-Barr virus encephalitis in solid organ transplantation

AU - Lau, Jillian S.Y.

AU - Low, Zhi Mei

AU - Abbott, Iain

AU - Shochet, Lani

AU - Kanellis, John

AU - Kitching, A. Richard

AU - Korman, Tony M.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes.

AB - Epstein-Barr virus (EBV) is typically associated with post transplant lymphoproliferative disease (PTLD) after solid organ and stem cell transplantation. However, it is rarely associated with neurological complications. We report a case of severe encephalitis complicating primary EBV infection six months post renal transplantation, and review the literature on EBV encephalitis in solid organ transplantation in adults. A 55-year-old male presented 6 months post cadaveric renal transplant with headache, fever and confusion. Neuroimaging was unremarkable, but an electroencephalogram was consistent with diffuse encephalopathy. EBV DNA was detected in both cerebrospinal fluid (13,177 copies/ml), and plasma (14,166 copies/ml). Management included reduction of immunosuppression, intravenous ganciclovir and intravenous immunoglobulin, and resulted in a reduction in EBV viral load in both plasma and cerebrospinal fluid. The patient made a full recovery with no long-term neurological deficits and preservation of the graft. This case highlights the importance of knowing donor and recipient EBV serostatus at time of transplant, and closely monitoring EBV DNA when there is a mismatch. Ganciclovir or valganciclovir prophylaxis has also been shown to reduce the incidence of primary EBV infection in renal transplantation in these recipients. Treatment options for EBV infection post-transplant include reduction of immunosuppression, antiviral therapy, IVIg, and monoclonal antibody therapy directed toward infected B lymphocytes.

KW - Encephalitis

KW - Epstein-Barr virus

KW - Immunosuppression

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=85029793950&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 212

EP - 217

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 3

ER -